Impact of postprandial glucose control on diabetes-related complications: How is the evidence evolving?

Journal of Diabetes and its Complications

Volumn 30, Issue 2, 2016, Pages 374-385

  Madsbad, Sten ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Cardiovascular disease; Clinical physiology; Glycemic control; Type 1 diabetes; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; GLUCAGON; GLUCOSE; INSULIN; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DIABETES MELLITUS; DIET; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; GLUCOSE BLOOD LEVEL; GLUCOTOXICITY; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN TREATMENT; MEAL; NEOPLASM; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGICAL PROCESS; POSTPRANDIAL HYPERGLYCEMIA; POSTPRANDIAL STATE; PRACTICE GUIDELINE; PRIORITY JOURNAL; BLOOD; DIABETES COMPLICATIONS; METABOLISM; PHYSIOLOGY;

BLOOD GLUCOSE; DIABETES COMPLICATIONS; DIABETES MELLITUS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; POSTPRANDIAL PERIOD;

EID: 84960897261     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2015.09.019     Document Type: Review

References (98)

1. A.M. Abbatecola, M.R. Rizzo, M. Barbieri, and et al. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics Neurology 67 2006 235 240
2. O. Ajala, P. English, and J. Pinkney Systematic review and meta-analysis of different dietary approaches to the management of type 2 diabetes The American Journal of Clinical Nutrition 97 2013 505 516
3. American Diabetes Association Standards of medical care in diabetes - 2015 Diabetes Care 38 2015 S1 S93
4. Authors/Task Force Members, L. Ryden, P.J. Grant, and et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD) European Heart Journal 34 2013 3035 3087
5. P. Bansal, and Q. Wang Insulin as a physiological modulator of glucagon secretion American Journal of Physiology. Endocrinology and Metabolism 295 2008 E751 E761
6. R.M. Bergenstal Glycemic variability and diabetes complications: does it matter? Simply put, there are better glycemic markers! Diabetes Care 38 2015 1615 1621
7. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, W. Harper, M. Clement, and et al. Policies, guidelines and consensus statements: pharmacologic management of type 2 diabetes - 2015 interim update Canadian Journal of Diabetes 39 2015 250 252
8. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, S.A. Imran, R. Rabasa-Lhoret, and S. Ross Targets for glycemic control Canadian Journal of Diabetes 37 2013 S31 S34
9. L.M. Castaneda-Gonzalez, M. Bacardi Gascon, and Cruz A. Jimenez Effects of low carbohydrate diets on weight and glycemic control among type 2 diabetes individuals: a systemic review of RCT greater than 12 weeks Nutrición Hospitalaria 26 2011 1270 1276
10. F. Cavalot, A. Pagliarino, M. Valle, and et al. Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study Diabetes Care 34 2011 2237 2243
11. F. Cavalot, A. Petrelli, M. Traversa, and et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study The Journal of Clinical Endocrinology and Metabolism 91 2006 813 819
12. A. Ceriello New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy Diabetes Care 26 2003 1589 1596
13. A. Ceriello Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 54 2005 1 7
14. A. Ceriello The glucose triad and its role in comprehensive glycaemic control: current status, future management International Journal of Clinical Practice 64 2010 1705 1711
15. A. Ceriello, A. Cavarape, L. Martinelli, and et al. The post-prandial state in type 2 diabetes and endothelial dysfunction: effects of insulin aspart Diabetic Medicine: a Journal of the British Diabetic Association 21 2004 171 175
16. A. Ceriello, M. Hanefeld, L. Leiter, and et al. Postprandial glucose regulation and diabetic complications Archives of Internal Medicine 164 2004 2090 2095
17. A. Ceriello, L. Quagliaro, B. Catone, and et al. Role of hyperglycemia in nitrotyrosine postprandial generation Diabetes Care 25 2002 1439 1443
18. C.H. Chang, Y.C. Chang, J.W. Lin, S.T. Chen, L.M. Chuang, and M.S. Lai Cardiovascular risk associated with acarbose versus metformin as the first-line treatment in patients with type 2 diabetes: a nationwide cohort study The Journal of Clinical Endocrinology and Metabolism 100 2015 1121 1129
19. J.L. Chiasson, R.G. Josse, R. Gomis, M. Hanefeld, A. Karasik, and Laakso M; STOP-NIDDM Trial Research Group Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial JAMA: The Journal of the American Medical Association 290 2003 486 494
20. Y.M. Cho, R.D. Wideman, and T.J. Kieffer Clinical application of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus Endocrinology and Metabolism 28 2013 262 274
21. M.K. Chu, C.R. Gordijo, J. Li, and et al. In vivo performance and biocompatibility of a subcutaneous implant for real-time glucose-responsive insulin delivery Diabetes Technology & Therapeutics 17 2015 255 267
22. N.D. Cohen, R. Audehm, E. Pretorius, J. Kaye, L.H. Chapman, and S. Colagiuri The rationale for combining GLP-1 receptor agonists with basal insulin The Medical Journal of Australia 199 2013 246 249
23. M. Coutinho, H.C. Gerstein, Y. Wang, and S. Yusuf The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years Diabetes Care 22 1999 233 240
24. DECODE Study Group EDEG Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria Lancet 354 1999 617 621
25. Decode Study Group EDEG Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 26 2003 688 696
26. Decode Study Group tEDEG Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria Archives of Internal Medicine 161 2001 397 405
27. L. Duca, R. Sippl, and J.K. Snell-Bergeon Is the risk and nature of CVD the same in type 1 and type 2 diabetes? Current Diabetes Reports 13 2013 350 361
28. Emerging Risk Factors Collaboration E. Di Angelantonio, P. Gao, and et al. Glycated hemoglobin measurement and prediction of cardiovascular disease JAMA: The Journal of the American Medical Association 311 2014 1225 1233
29. K. Esposito, D. Giugliano, F. Nappo, R. Marfella, and Campanian Postprandial Hyperglycemia Study Group Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus Circulation 110 2004 214 219
30. R.D. Feinman, W.K. Pogozelski, A. Astrup, and et al. Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base Nutrition 31 2015 1 13
31. S.M. Gapstur, P.H. Gann, W. Lowe, K. Liu, L. Colangelo, and A. Dyer Abnormal glucose metabolism and pancreatic cancer mortality JAMA: The Journal of the American Medical Association 283 2000 2552 2558
32. A.S. Grewal, B.S. Sekhon, and V. Lather Recent updates on glucokinase activators for the treatment of type 2 diabetes mellitus Mini Reviews in Medicinal Chemistry 14 2014 585 602
33. Y. Handelsman, Z.T. Bloomgarden, G. Grunberger, and et al. American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015 Endocrine practice: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 21 2015 1 87
34. M. Hanefeld, J.L. Chiasson, C. Koehler, E. Henkel, F. Schaper, and T. Temelkova-Kurktschiev Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance Stroke; a Journal of Cerebral Circulation 35 2004 1073 1078
35. M. Hanefeld, S. Fischer, U. Julius, and et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up Diabetologia 39 1996 1577 1583
36. T. Heise, U. Hovelmann, L. Brondsted, C.L. Adrian, L. Nosek, and H. Haahr Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart Diabetes, Obesity & Metabolism 17 2015 682 688
37. Y. Hirakawa, T. Ninomiya, N. Mukai, and et al. Association between glucose tolerance level and cancer death in a general Japanese population: the Hisayama Study American Journal of Epidemiology 176 2012 856 864
38. I.B. Hirsch Glycemic variability and diabetes complications: does it matter? Of course it does! Diabetes Care 38 2015 1610 1614
39. R.R. Holman, M.A. Bethel, J.C. Chan, and et al. Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial American Heart Journal 168 2014 23 29.e22
40. M. Hultstrom, N. Roxhed, and L. Nordquist Intradermal insulin delivery: a promising future for diabetes management Journal of Diabetes Science and Technology 8 2014 453 457
41. International Diabetes Federation Guideline Development Group Guideline for management of postmeal glucose in diabetes Diabetes Research and Clinical Practice 103 2014 256 268
42. Investigators F-ST Design of FLAT-SUGAR: randomized trial of prandial insulin versus prandial GLP-1 receptor agonist together with basal insulin and metformin for high-risk type 2 diabetes Diabetes Care 38 2015 1558 1566
43. R. Kawamori, K. Node, T. Hanafusa, Y. Atsumi, Y. Naito, and Y. Oka Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study Cardiovascular Diabetology 12 2013 131
44. R.P. Kelly, P. Garhyan, E. Raddad, and et al. Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes Diabetes, Obesity & Metabolism 17 2015 414 422
45. E.S. Kilpatrick Arguments for and against the role of glucose variability in the development of diabetes complications Journal of Diabetes Science and Technology 3 2009 649 655
46. C. Kim, J.H. Sohn, M.U. Jang, and et al. Association between visit-to-visit glucose variability and cognitive function in aged type 2 diabetic patients: a cross-sectional study PLoS One 10 2015 e0132118
47. M. Kitada, Z. Zhang, A. Mima, and G.L. King Molecular mechanisms of diabetic vascular complications Journal of Diabetes Investigation 1 2010 77 89
48. M. Lajous, W. Willett, E. Lazcano-Ponce, L.M. Sanchez-Zamorano, M. Hernandez-Avila, and I. Romieu Glycemic load, glycemic index, and the risk of breast cancer among Mexican women Cancer Causes & Control: CCC 16 2005 1165 1169
49. C.A. Leech, I. Dzhura, O.G. Chepurny, and et al. Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic beta cells Progress in Biophysics and Molecular Biology 107 2011 236 247
50. L.A. Leiter, A. Ceriello, J.A. Davidson, and et al. Postprandial glucose regulation: new data and new implications Clinical Therapeutics 27 2005 S42 S56
51. C.M. Lin, H.L. Huang, F.Y. Chu, and et al. Association between gastroenterological malignancy and diabetes mellitus and anti-diabetic therapy: a nationwide, population-based cohort study PLoS One 10 2015 e0125421
52. D. Lorber Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 7 2014 169 183
53. Y. Ma, S. Fang, S. Zhao, and et al. A recombinant slow-release PACAP-derived peptide alleviates diabetes by promoting both insulin secretion and actions Biomaterials 51 2015 80 90
54. C.S. Marathe, C.K. Rayner, K.L. Jones, and M. Horowitz Relationships between gastric emptying, postprandial glycemia, and incretin hormones Diabetes Care 36 2013 1396 1405
55. J.J. Meier, and M.A. Nauck Incretin-based therapies: where will we be 50 years from now? Diabetologia 58 2015 1745 1750
56. J.J. Meier, J. Rosenstock, A. Hincelin-Mery, and et al. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized. open-label trial Diabetes Care 38 2015 1263 1273
57. J.B. Meigs, D.M. Nathan, R.B. D'Agostino Sr., P.W. Wilson, and Framingham Offspring S. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study Diabetes Care 25 2002 1845 1850
58. D.S. Michaud, C.S. Fuchs, S. Liu, W.C. Willett, G.A. Colditz, and E. Giovannucci Dietary glycemic load, carbohydrate, sugar, and colorectal cancer risk in men and women Cancer Epidemiology, Biomarkers & Prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 14 2005 138 147
59. L. Monnier, C. Colette, A. Comenducci, D. Vallee, and S. Dejager Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose? Diabetes Technology & Therapeutics 14 2012 943 950
60. L. Monnier, C. Colette, S. Dejager, and D.R. Owens "Mild dysglycemia" in type 2 diabetes: to be neglected or not? Journal of Diabetes and its Complications 29 2015 451 458
61. L. Monnier, C. Colette, and D. Owens Postprandial and basal glucose in type 2 diabetes: assessment and respective impacts Diabetes Technology & Therapeutics 13 2011 S25 S32
62. L. Monnier, H. Lapinski, and C. Colette Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c) Diabetes Care 26 2003 881 885
63. L. Monnier, E. Mas, C. Ginet, and et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes JAMA: The Journal of the American Medical Association 295 2006 1681 1687
64. M.C. Moore, K.C. Coate, J.J. Winnick, Z. An, and A.D. Cherrington Regulation of hepatic glucose uptake and storage in vivo Advances in Nutrition 3 2012 286 294
65. E.G. Moser, A.A. Morris, and S.K. Garg Emerging diabetes therapies and technologies Diabetes Research and Clinical Practice 97 2012 16 26
66. H. Mudaliar, C. Pollock, J. Ma, H. Wu, S. Chadban, and U. Panchapakesan The role of TLR2 and 4-mediated inflammatory pathways in endothelial cells exposed to high glucose PLoS One 9 2014 e108844
67. N. Nakamura, Y. Ueno, Y. Tsuchiyama, Y. Koike, M. Gohda, and O. Satani Isolated post-challenge hyperglycemia in patients with normal fasting glucose concentration exaggerates neointimal hyperplasia after coronary stent implantation Circulation Journal: official journal of the Japanese Circulation Society 67 2003 61 67
68. L. Nalysnyk, M. Hernandez-Medina, and G. Krishnarajah Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature Diabetes, Obesity & Metabolism 12 2010 288 298
69. NAVIGATOR Study Group, R.R. Holman, S.M. Haffner, and et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events The New England Journal of Medicine 362 2010 1463 1476
70. R. Nishimura, Y. Tanaka, K. Koiwai, and et al. Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study Cardiovascular Diabetology 14 2015 11
71. W. Nuffer, J.M. Trujillo, and S.L. Ellis Technosphere insulin (Afrezza): a new, inhaled prandial insulin The Annals of Pharmacotherapy 49 2015 99 106
72. S. Ogawa, K. Nako, M. Okamura, T. Sakamoto, and S. Ito Stabilization of postprandial blood glucose fluctuations by addition of glucagon like polypeptide-analog administration to intensive insulin therapy Journal of Diabetes Investigation 6 2015 436 442
73. S. Okazaki, T. Takahashi, T. Iwamura, and et al. HIS-388, a novel orally active and long-acting 11beta-hydroxysteroid dehydrogenase type 1 inhibitor, ameliorates insulin sensitivity and glucose intolerance in diet-induced obesity and nongenetic type 2 diabetic murine models The Journal of Pharmacology and Experimental Therapeutics 351 2014 181 189
74. V. Pandyarajan, and M.A. Weiss Design of non-standard insulin analogs for the treatment of diabetes mellitus Current Diabetes Reports 12 2012 697 704
75. J.A. Pfefferkorn Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes Expert Opinion on Drug Discovery 8 2013 319 330
76. I. Raz, A. Ceriello, P.W. Wilson, and et al. Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/premeal glycemia Diabetes Care 34 2011 1511 1513
77. I. Raz, P.W. Wilson, K. Strojek, and et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial Diabetes Care 32 2009 381 386
78. R.A. Rizza Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy Diabetes 59 2010 2697 2707
79. J. Rosenstock, L. Hansen, P. Zee, and et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin Diabetes Care 38 2015 376 383
80. G. Rudofsky Jr., P. Reismann, S. Schiekofer, and et al. Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-kappaB activation in PBMCs Hormone and Metabolic Research 36 2004 630 638
81. A.D. Sanlioglu, B. Karacay, M.K. Balci, T.S. Griffith, and S. Sanlioglu Therapeutic potential of VIP vs PACAP in diabetes Journal of Molecular Endocrinology 49 2012 R157 R167
82. T. Santos Cavaiola, and S. Edelman Inhaled insulin: a breath of fresh air? A review of inhaled insulin Clinical Therapeutics 36 2014 1275 1289
83. F.C. Sasso, O. Carbonara, R. Nasti, and et al. Glucose metabolism and coronary heart disease in patients with normal glucose tolerance JAMA: The Journal of the American Medical Association 291 2004 1857 1863
84. E.R. Seaquist Addressing the burden of diabetes JAMA: The Journal of the American Medical Association 311 2014 2267 2268
85. W.H. Sheu, A. Rosman, A. Mithal, and et al. Addressing the burden of type 2 diabetes and cardiovascular disease through the management of postprandial hyperglycaemia: an Asian-Pacific perspective and expert recommendations Diabetes Research and Clinical Practice 92 2011 312 321
86. T. Shiraiwa, H. Kaneto, T. Miyatsuka, and et al. Post-prandial hyperglycemia is an important predictor of the incidence of diabetic microangiopathy in Japanese type 2 diabetic patients Biochemical and Biophysical Research Communications 336 2005 339 345
87. 1c in Japanese type 2 diabetic patients Diabetes Care 28 2005 2806 2807
88. C. Sorli New developments in insulin therapy for type 2 diabetes The American Journal of Medicine 127 2014 S39 S48
89. E. Standl, and O. Schnell Alpha-glucosidase inhibitors 2012 - cardiovascular considerations and trial evaluation Diabetes & Vascular Disease Research 9 2012 163 169
90. E. Standl, O. Schnell, and A. Ceriello Postprandial hyperglycemia and glycemic variability: should we care? Diabetes Care 34 2011 S120 S127
91. I.M. Stratton, A.I. Adler, H.A. Neil, and et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 321 2000 405 412
92. A.A. Tahrani, C.J. Bailey, S. Del Prato, and A.H. Barnett Management of type 2 diabetes: new and future developments in treatment Lancet 378 2011 182 197
93. M.A. Tambascia, D.A. Malerbi, and F.G. Eliaschewitz Influence of gastric emptying on the control of postprandial glycemia: physiology and therapeutic implications Einstein 12 2014 251 253
94. J. Tay, N.D. Luscombe-Marsh, C.H. Thompson, and et al. A very low carbohydrate, low saturated fat diet for type 2 diabetes management: a randomized trial Diabetes Care 37 2014 2909 2918
95. 1c level Diabetes Care 23 2000 1830 1834
96. I. Tkac, Z. Milicevic, and G. Jermendy How to interpret results of the HEART2D trial? Diabetes Research and Clinical Practice 86 2009 S53 S56
97. D. Yabe, and Y. Seino Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and beta cell preservation Progress in Biophysics and Molecular Biology 107 2011 248 256
98. Biodel Inc. Website Pipeline Available at: http://www.biodel.com/content/pipeline/rhi-based-ultra-rapid-acting-insulin.htm (Accessed September 1, 2015)